Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Synthesis of [11C]SSR149415 and preliminary imaging studies using positron emission tomography.

Schönberger M, Leggett C, Kim SW, Hooker JM.

Bioorg Med Chem Lett. 2010 May 15;20(10):3103-6. doi: 10.1016/j.bmcl.2010.03.108. Epub 2010 Apr 2.

PMID:
20400305
2.

An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders.

Serradeil-Le Gal C, Wagnon J 3rd, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A.

CNS Drug Rev. 2005 Spring;11(1):53-68. Review.

3.

Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders.

Griebel G, Stemmelin J, Gal CS, Soubrié P.

Curr Pharm Des. 2005;11(12):1549-59. Review.

PMID:
15892661
4.

The vasopressin V1b receptor as a therapeutic target in stress-related disorders.

Griebel G, Simiand J, Stemmelin J, Gal CS, Steinberg R.

Curr Drug Targets CNS Neurol Disord. 2003 Jun;2(3):191-200. Review.

PMID:
12769799
5.

Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression.

Hodgson RA, Higgins GA, Guthrie DH, Lu SX, Pond AJ, Mullins DE, Guzzi MF, Parker EM, Varty GB.

Pharmacol Biochem Behav. 2007 Mar;86(3):431-40. Epub 2007 Jan 9.

PMID:
17291571
6.

SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model.

Breuer ME, van Gaalen MM, Wernet W, Claessens SE, Oosting RS, Behl B, Korte SM, Schoemaker H, Gross G, Olivier B, Groenink L.

Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):101-6. doi: 10.1007/s00210-008-0336-1. Epub 2008 Jul 31.

PMID:
18668225
7.

The pituitary mediates the anxiolytic-like effects of the vasopressin V1B receptor antagonist, SSR149415, in a social interaction test in rats.

Shimazaki T, Iijima M, Chaki S.

Eur J Pharmacol. 2006 Aug 14;543(1-3):63-7. Epub 2006 Jun 27.

PMID:
16843459
8.

An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model.

Iijima M, Chaki S.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):622-7. Epub 2006 Dec 15.

PMID:
17229509
9.

Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression.

Alonso R, Griebel G, Pavone G, Stemmelin J, Le Fur G, Soubrié P.

Mol Psychiatry. 2004 Mar;9(3):278-86, 224.

PMID:
14699428
10.

Involvement of vasopressin 3 receptors in chronic psychological stress-induced visceral hyperalgesia in rats.

Bradesi S, Martinez V, Lao L, Larsson H, Mayer EA.

Am J Physiol Gastrointest Liver Physiol. 2009 Feb;296(2):G302-9. doi: 10.1152/ajpgi.90557.2008. Epub 2008 Nov 25.

11.

Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.

Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C, Guillon G, Barberis C, Brossard G, Soubrié P, Nisato D, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 2002 Mar;300(3):1122-30.

12.

Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat.

Overstreet DH, Griebel G.

Pharmacol Biochem Behav. 2005 Sep;82(1):223-7. Epub 2005 Sep 21.

PMID:
16181667
13.

Effect of vasopressin V1b receptor antagonist, SSR149415, on anxiety-like behavior and Lewis lung carcinoma metastasis in mice.

Amikishieva AV, Ilnitskaya SI, Nikolin VP, Popova NA.

Exp Oncol. 2011 Sep;33(3):126-9.

PMID:
21956463
14.
15.

Biological characterization of rodent and human vasopressin V1b receptors using SSR-149415, a nonpeptide V1b receptor ligand.

Serradeil-Le Gal C, Raufaste D, Derick S, Blankenstein J, Allen J, Pouzet B, Pascal M, Wagnon J, Ventura MA.

Am J Physiol Regul Integr Comp Physiol. 2007 Aug;293(2):R938-49. Epub 2007 May 23.

16.

Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats.

Salomé N, Stemmelin J, Cohen C, Griebel G.

Psychopharmacology (Berl). 2006 Aug;187(2):237-44. Epub 2006 Jun 2.

PMID:
16779555
17.

The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice.

Urani A, Philbert J, Cohen C, Griebel G.

Pharmacol Biochem Behav. 2011 May;98(3):425-31. doi: 10.1016/j.pbb.2011.02.019. Epub 2011 Feb 26.

PMID:
21356230
18.

Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.

Serradeil-Le Gal C, Wagnon J, Valette G, Garcia G, Pascal M, Maffrand JP, Le Fur G.

Prog Brain Res. 2002;139:197-210. Review.

PMID:
12436936
19.

The discovery of novel vasopressin V1b receptor ligands for pharmacological, functional and structural investigations.

Guillon G, Derick S, Pena A, Cheng LL, Stoev S, Seyer R, Morgat JL, Barberis C, Gal CS, Wagnon J, Manning M.

J Neuroendocrinol. 2004 Apr;16(4):356-61. Review.

PMID:
15089974
20.

Involvement of vasopressin V1b receptor in anti-anxiety action of SSRI and SNRI in mice.

Ishizuka Y, Abe H, Tanoue A, Kannan H, Ishida Y.

Neurosci Res. 2010 Mar;66(3):233-7. doi: 10.1016/j.neures.2009.11.004. Epub 2009 Nov 13.

PMID:
19914307

Supplemental Content

Support Center